Global Systems Dynamics Inc Warrants (01/04/2026) Stock (OTC: GSDWW)

Latest news for Global Systems Dynamics Inc Warrants (01/04/2026) (OTC:GSDWW) Stock

Global Systems Dynamics Inc Warrants (01/04/2026)

Oppenheimer analyst Rayna Kumar maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Outperform and raises the price target from $120 to $121.

News

Price Target

Analyst Ratings

FOUR

Oppenheimer Maintains Outperform on Shift4 Payments, Raises Price Target to $121

Movers

Trading Ideas

ZCAR

Zoomcar Holdings Shares Halted On A Circuit Breaker

MoneyLion Partners With MrBeast For $4.2M At-Home Giveaway Tied To New 'Beast Games' Show, Offering Over 1,000 Prizes In Year-Long Sweepstakes With Daily Free Entries For Viewers And MoneyLion Users

Oppenheimer analyst Dominick Gabriele maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Outperform and lowers the price target from $591 to $588.

Oppenheimer Maintains Outperform on Mastercard, Lowers Price Target to $588

Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) shares are trading lower by 1.48% to $163.11 during Wednesday&#8217;s session following the Federal Reserve&#8217;s cautious pivot on <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral">interest rate policy</a>, alongside broader sector challenges.
What To Know: With the Fed signaling a slower pace of rate cuts, the federal funds rate remains elevated at 4.25%-4.5%. While this signals progress toward a neutral monetary stance, it also prolongs higher borrowing costs, which may dampen capital spending. Companies reliant on large-scale investments in technology, like semiconductor equipment firms, are particularly exposed.
Adding to the strain, Micron Technology&#8217;s disappointing <a href="https://www.benzinga.com/24/12/42594359/micron-stock-is-moving-lower-thursday-whats-driving-the-action">second-quarter guidance</a> highlights ongoing weakness in consumer-driven markets and a slower recovery timeline for the semiconductor sector.
While Micron&#8217;s long-term prospects hinge on AI-driven growth, its near-term struggles could cascade across the supply chain, including suppliers like Applied Materials.
With the labor market cooling and inflation still above target, investors may adopt a risk-averse stance, questioning demand stability for chip-making equipment.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42585715/us-gdp-upwardly-revised-to-31-in-q3-jobless-claims-drop-more-than-expected-treasury-yields-hit-7-month-highs">US GDP Revised To 3.1%, Jobless Claims Dip More Than Expected, Treasury Yields Hit 7-Month High</a>
<h2 class="wp-block-heading">How To Buy AMAT Stock</h2>
By now you're likely curious about how to participate in the market for Applied Materials &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMAT has a 52-week high of $255.89 and a 52-week low of $148.06.

AMAT

What's Going On With Applied Materials (AMAT) Stock?

JP Morgan analyst Phil Gresh maintains Canadian Natural Res (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#TSX">CNQ</a>) with a Neutral and raises the price target from C$51 to C$53.

TSX:CNQ

JP Morgan Maintains Neutral on Canadian Natural Res, Raises Price Target to C$53

Oppenheimer analyst Rayna Kumar maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Outperform and raises the price target from $214 to $239.

Oppenheimer Maintains Outperform on Fiserv, Raises Price Target to $239

In the current market session, Verisk Analytics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) share price is at $275.67, after a 0.04% spike. Moreover, over the past month, the stock fell by 4.14%, but in the past year, spiked by 16.71%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734627613_0.png" alt="Past Year Chart" />

<h3>Comparing Verisk Analytics P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 39.2 in the Professional Services industry, Verisk Analytics Inc. has a higher P/E ratio of 42.53. Shareholders might be inclined to think that Verisk Analytics Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734627613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

VRSK

P/E Ratio Insights for Verisk Analytics

A Georgia state appeals court has removed Fulton County District Attorney Fani Willis from the election interference case against President-elect Donald Trump, citing an "appearance of impropriety" as the <a href="https://www.benzinga.com/topic/fani-willis">basis for the decision. </a>
The court emphasized that disqualification was necessary to restore public confidence, but the indictment itself remains intact, leaving the case's future in question, the Associated Press <a href="https://apnews.com/article/trump-fani-willis-georgia-election-indictment-removed-0aa6db3b7abed22eb08ed9323f687972">reports</a>.
What Happened: In a 2-1 ruling, the Georgia Court of Appeals found that Willis&#8217;s involvement created concerns over impartiality. The decision mandates the Prosecuting Attorneys' Council of Georgia to assign a new prosecutor to the case, potentially delaying proceedings further if Willis appeals to the state Supreme Court.
The legal challenge stems from allegations that her prior romantic relationship with special prosecutor Nathan Wade influenced pretrial decisions, the AP reports.
The indictment, issued in August 2023, accuses Trump and 18 others of attempting to overturn the 2020 presidential election results in Georgia. Four defendants have since pleaded guilty, while Trump and the others maintain their innocence. 
Superior Court Judge Scott McAfee had previously allowed Willis to remain on the case, a decision now overruled by the appeals court.
Manhattan District Attorney Alvin Bragg&#8216;s response to similar legal arguments further complicates Trump&#8217;s broader legal battles. In New York, Bragg argued that overwhelming evidence of guilt in the hush money case involving adult film actress Stormy Daniels supersedes <a href="https://www.benzinga.com/24/12/42521426/trumps-hush-money-conviction-upheld-amid-presidential-immunity-controversy-alvin-bragg-says-overwhelming-evidence-of-guilt">claims of presidential immunity.</a>
Also Read: <a href="https://www.benzinga.com/24/12/42568430/senate-minority-leader-mcconnell-urges-supreme-court-to-reject-tiktoks-delay-request-pushing-for-january-ban-amid-first-amendment-debate">Mitch McConnell Urges Supreme Court To Reject TikTok&#8217;s Delay Request</a>
Why It Matters: Trump has celebrated the Georgia court's decision, calling for the case to end entirely. While this marks a victory for the president-elect, experts note the ruling may only delay, rather than halt, proceedings, according to the AP. The case also impacts the remaining 14 co-defendants, who continue to face serious charges.
The broader implications extend beyond Georgia, with Trump facing ongoing legal challenges in New York and Washington, D.C. His legal team continues to argue for presidential immunity in these cases. They&#8217;re also seeking to shield him from prosecution as he prepares to return to the White House.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42405278/trump-plays-presidential-immunity-card-in-truth-social-lawsuit-battle">Trump Plays Presidential Immunity Card In Truth Social Lawsuit Battle</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Trump Prosecutor Fani Willis Removed From Election Case, Indictment Stands

Cannabis regulators and industry advocates have, for a long time, contended that <a href="https://www.benzinga.com/cannabis">licensed marijuana products</a> are safer and cleaner than those circulating on the illicit market. Logical, right? Not necessarily. An analysis published Thursday by the Los Angeles Times challenges that claim and reveals comparable pesticide contamination rates in legal and illicit cannabis.
Testing 16 products from unlicensed sellers and tobacco shops, the Times <a href="https://www.latimes.com/california/story/2024-12-19/legal-and-illegal-cannabis-products-pose-hidden-health-risks">found</a> that half had no detectable pesticides, mirroring the pesticide-free rate in California's legal market. This, despite California&#8217;s tests for 66 pesticides in licensed products, which fail to detect other harmful compounds identified in the Times investigation.
This similarity apparently "doesn't shock" Josh Swider, CEO and cofounder of Infinite Chemical Analysis Labs, which tests cannabis in California and Michigan. "Normally, the illicit market is just buying from the legal market brokers. It's not like there really are two different markets," he said, according to the Times.
California's Department of Cannabis Control naturally defends the regulated market, stating that its oversight ensures "far greater consumer safety than the unregulated alternative." 
<h2 class="wp-block-heading">Logical? Not Quite</h2>
Some unregulated products were pesticide-free because they contained synthetic THC variants, such as Delta-8, derived from chemically processed hemp. These compounds, while inexpensive to produce, carry unknown health risks due to these chemical byproducts. "It's not a pesticide problem, but it has other health implications," Swider said.
Notably, synthetic THC is not confined to the illicit market. The Times report uncovered lab-created cannabinoids in vape pens sold by various legal brands. While synthetic THC is banned in California's legal market, the state doesn't screen for it, hence not so logical. 
Michigan regulators, on the other hand, have validated tests to identify these compounds.
<h2 class="wp-block-heading">Health Hazards</h2>
The analysis also uncovered troubling health hazards. The Times looked at a vape from an unlicensed East LA shop that contained vitamin E acetate, which was linked to severe lung injuries, thousands of hospitalizations and 68 deaths during the <a href="https://www.benzinga.com/markets/cannabis/19/12/14909104/ask-new-frontier-data-experts-vaping-crisis-update">2019 vape crisis</a>. The state of California does not screen for Vitamin E acetate, which is used to dilute vape cartridges.
Ironically, the most pesticide-laden products came from legal sellers. One brand, Backpack Boyz vape bought at a licensed shop contained 32 pesticides. State regulators quickly shut down the manufacturer, though Backpack Boyz claimed the contaminated products were counterfeits, according to the LA Times.
Pesticide types varied between markets, with illicit products often containing banned chemicals from California's screening list. In contrast, legal products were often found to contain unscreened pesticides like pymetrozine, a carcinogenic insecticide that did not show up in any unregulated cannabis products.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41555499/all-once-again-warned-unregulated-cannabis-vapes-contain-dangerous-pesticides-study-says">All Once Again Warned: Unregulated Cannabis Vapes Contain Dangerous Pesticides, Study Says</a></li>
</ul>
Photo AI generated via Dall-E.

Cannabis

Government

Pesticides In Pot: Overlooked Dangers Of California's Legal Weed

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Buy and maintains $80 price target.

Reiteration

GPCR

HC Wainwright & Co. Reiterates Buy on Structure Therapeutics, Maintains $80 Price Target

FWONA

Liberty Media Confirms European Commission Phase II Investigation Into MotoGP Acquisition, Extends Longstop Date To June 30, 2025

Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares are trading higher after the company received a $9.00 per share acquisition offer from a new third-party consortium, an 83% premium to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42576367/soho-house-co-inc-announcement-on-offer-from-a-third-party-consortium-to-acquire-the-company" rel="noreferrer noopener">December 18, 2024, closing price</a>.
Supported by the company&#8217;s Executive Chairman, Ron Burkle and The Yucaipa Companies, the offer follows a strategic review by Yucaipa and its advisors, aiming to better reflect the company&#8217;s inherent value.
In response to the offer, which is contingent on key shareholders rolling over their equity interests, the Board of Directors has established an independent Special Committee to evaluate the proposal.
Also, the company reported third-quarter EPS&nbsp;of $0.00 beating the street view of a loss of $0.01 and sales&nbsp;of $333.4 million missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42576891/soho-house-co-inc-announces-third-quarter-2024-results" rel="noreferrer noopener">consensus of $334.87 million</a>.
Membership revenues rose 16.7% year-over-year to <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">$107.4 million in the quarter</a>.
In the third quarter, total members increased 4.8% year-over-year to 267,494, and Soho House members grew 13% year-over-year to 208,078.
The membership waitlist remains at a record level of approximately 111,000.
At the end of the third-quarter of 2024, Soho House had cash and cash equivalents, including restricted cash, of $147 million.
During the quarter, the company repurchased approximately 2.3 million shares for $13 million.
Outlook: Soho House updated its FY24 revenue guidance to around $1.2 billion (vs. the consensus estimate of $1.23 billion), narrowing from its <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">previous range of $1.2 billion to $1.25 billion</a>.
Price Action: SHCO shares are up 58.4% at $7.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42593013" target="_blank" rel="noreferrer noopener">Luigi Mangione Faces Extradition, Possible Federal Charges May Carry Death Penalty</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Guidance

Small Cap

SHCO

Soho House Jumps On Receiving Acquisition Offer With 83% Premium

Shares of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) are trading flat on Thursday, but remain in a downtrend.
If the stock eventually reaches levels around $95.00, there is a good chance it reverses and heads higher. As you can see on the chart, this is what happened in late November. This is why our technical analysis team has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png" alt="Merck" class="wp-image-700197" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14.png 1491w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
There has been a lot of news coming from Merck.
The advanced cancer genomic testing provider Personalis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) said it received a $50 million equity investment from Merck.&nbsp; When the deal closes, Merck will own 16.5% of Personalis.
Merck also announced that <a href="https://www.benzinga.com/24/12/42554599/whats-going-on-with-merck-shares-wednesday">it is entering the lucrative obesity market</a>. It is licensing rights from Chinese biotech Hansoh Pharmaceutical Group Company Limited&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNSPF#OTC">HNSPF</a>)to an investigational oral GLP – 1 receptor.
The chart of Merck offers some simple but valuable technical analysis lessons. Price levels that had been resistance can convert into support. Also, stocks that drop to support have a tendency to rally.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases">Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases</a>
$119.40 was resistance in May 2023. Some of the investors who sold then were happy when the price fell soon after. They thought they made a good decision.
But in January 2024 the resistance broke and the stock moved higher. When this happened, some of these sellers came to think they made a mistake and decided to buy their shares back if they can do so at the same price they sold them for.
So, when the stock dropped back to around $119.40 in March 2024 they placed buy orders. The large concentration of these orders formed support at the same price that had been resistance.
Similar action occurred at the $111.00 level. It was resistance in August 2023. Then it became support a year later in August 2024.
In July 2022, the $95.00 level was resistance. It converted into support last month, and it may be support again if Merck reaches it.
As you can also see on the chart, sometimes stocks rally after they reach support. This happens when some of the buyers who created the support think they will get outbid. If someone else is willing to pay a higher price, that's who the sellers will go to.
As a result, they increase the prices they are willing to pay. Others see this and do the same. It can cause a snowball effect that pushes the stock higher and it may be about to happen with Merck.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42595485/bitcoin-rebounds-above-102000-post-fed-meeting-us-gdp-hits-31-jobless-claims-drop-treasury-yields-peak-teslas-eu-registrations-fall-41-q4-ev-target-in-doubt-top-headlines-today-while-us-slept">Bitcoin Rebounds Above $102,000 Post-Fed Meeting; Us GDP Hits 3.1%, Jobless Claims Drop, Treasury Yields Peak &#8211; Top Headlines Today While US Slept</a></li>
</ul>
Image: Courtesy of Merck.

Technicals

HNSPF

PSNL

Stock Of The Day: Where Does The Merck Downtrend End?

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and maintains $12 price target.

IMNN

HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $12 Price Target

Oppenheimer analyst Rayna Kumar maintains Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) with a Outperform and lowers the price target from $135 to $128.

EEFT

Oppenheimer Maintains Outperform on Euronet Worldwide, Lowers Price Target to $128

Oppenheimer analyst Rayna Kumar upgrades Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) from Perform to Outperform and announces $115 price target.

Upgrades

Oppenheimer Upgrades Block to Outperform, Announces $115 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Whales with a lot of money to spend have taken a noticeably bullish stance on Schlumberger.
Looking at options history for Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 12 are puts, for a total amount of $798,050 and 5, calls, for a total amount of $1,117,614.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $47.5 for Schlumberger, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Schlumberger's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Schlumberger's significant trades, within a strike price range of $25.0 to $47.5, over the past month.
<h3>Schlumberger Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626823_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$0.99</td>
<td>$0.91</td>
<td>$0.97</td>
<td>$47.50</td>
<td>$970.0K</td>
<td align="right">519</td>
<td>10.0K</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$10.55</td>
<td>$10.5</td>
<td>$10.55</td>
<td>$47.50</td>
<td>$211.0K</td>
<td align="right">907</td>
<td>122</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.45</td>
<td>$8.25</td>
<td>$8.47</td>
<td>$45.00</td>
<td>$64.3K</td>
<td align="right">663</td>
<td>92</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.7</td>
<td>$47.50</td>
<td>$58.8K</td>
<td align="right">907</td>
<td>479</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.7</td>
<td>$47.50</td>
<td>$58.8K</td>
<td align="right">907</td>
<td>424</td>
</tr>
</tbody>
</table>

<h3>About Schlumberger</h3>
SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts well over $1 billion in digital-related revenue.
In light of the recent options history for Schlumberger, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Schlumberger</h3>
<ul>
<li>With a volume of 5,601,300, the price of SLB is up 0.78% at $37.62. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for Schlumberger</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $50.666666666666664.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Schlumberger, targeting a price of $53. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Schlumberger, maintaining a target price of $53. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Schlumberger, which currently sits at a price target of $46. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Schlumberger with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Looking At Schlumberger's Recent Unusual Options Activity

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) with a Buy and maintains $7 price target.

Comments

Global Systems Dynamics Inc Warrants (01/04/2026)

News

Latest news for Global Systems Dynamics Inc Warrants (01/04/2026) (OTC:GSDWW) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga